Polarization-Sensitive OCT Imaging of Scleral Abnormalities in Eyes With High Myopia and Dome-Shaped Macula

JAMA Ophthalmology, Год журнала: 2024, Номер 142(4), С. 310 - 310

Опубликована: Март 7, 2024

The relevance of visualizing scleral fiber orientation may offer insights into the pathogenesis pathologic myopia, including dome-shaped maculopathy (DSM).

Язык: Английский

---

A Competition for the Diagnosis of Myopic Maculopathy by Artificial Intelligence Algorithms

JAMA Ophthalmology, Год журнала: 2024, Номер 142(11), С. 1006 - 1006

Опубликована: Сен. 26, 2024

Importance Myopic maculopathy (MM) is a major cause of vision impairment globally. Artificial intelligence (AI) and deep learning (DL) algorithms for detecting MM from fundus images could potentially improve diagnosis assist screening in variety health care settings. Objectives To evaluate DL classification segmentation compare their performance with that ophthalmologists. Design, Setting, Participants The Maculopathy Analysis Challenge (MMAC) was an international competition to develop automated solutions 3 tasks: (1) classification, (2) plus lesions, (3) spherical equivalent (SE) prediction. were provided subdatasets containing 2306, 294, 2003 images, respectively, which build algorithms. A group 5 ophthalmologists evaluated the same test sets tasks 1 2 ascertain performance. Results model ensembles, combined outcomes multiple submitted by MMAC participants, compared each individual algorithm. This study conducted March 1, 2023, 30, 2024, data analyzed January 15, 2024. Exposure as part or ophthalmologist interpretation. Main Outcomes Measures quadratic-weighted κ (QWK), F1 score, sensitivity, specificity. lesions dice similarity coefficient (DSC), SE prediction R mean absolute error (MAE). completed 7, 4, 4 teams, respectively. achieved QWK range 0.866 0.901, score 0.675 0.781, sensitivity 0.667 0.778, specificity 0.931 0.945. DSC 0.664 0.687 lacquer cracks (LC), 0.579 0.673 choroidal neovascularization, 0.768 0.841 Fuchs spot (FS). 0.791 0.874 MAE 0.708 0.943. Model ensemble results best algorithms, outperformed at (0.801; 95% CI, 0.764-0.840 vs 0.727; 0.684-0.768; P = .006) (0.946; 0.939-0.954 0.933; 0.925-0.941; .009), LC (DSC, 0.698; 0.649-0.745 DSC, 0.570; 0.515-0.625; < .001), FS 0.863; 0.831-0.888 0.790; 0.742-0.830; .001). Conclusions Relevance In this diagnostic study, 15 AI models on public dataset made available validated evaluated, some achieving better than

Язык: Английский

---

Advances in OCT Imaging in Myopia and Pathologic Myopia

Diagnostics, Год журнала: 2022, Номер 12(6), С. 1418 - 1418

Опубликована: Июнь 8, 2022

Advances in imaging with optical coherence tomography (OCT) and angiography (OCTA) technology, including the development of swept source OCT/OCTA, widefield or ultra-widefield systems, have greatly improved understanding, diagnosis, treatment myopia myopia-related complications. Anterior segment OCT is useful for anterior myopes, providing basis implantable collamer lens optimization, detecting intraocular decentration high myopic patients. has enhanced vitreous properties, measurement choroidal thickness eyes. Widefield systems visualization peripheral retinal lesions enabled evaluation wide staphyloma ocular curvature. Based on imaging, a new classification system guidelines management traction maculopathy been proposed; different dome-shaped macula morphologies described; abnormalities optic nerve peripapillary region demonstrated. OCTA can quantitatively evaluate microvasculature choriocapillaris, which early detection neovascularization anti-vascular endothelial growth factor therapy these In addition, application artificial intelligence OCT/OCTA achieved promising results.

Язык: Английский

---

The underestimated role of myopia in uncorrectable visual impairment in the United States

Scientific Reports, Год журнала: 2023, Номер 13(1)

Опубликована: Сен. 15, 2023

We estimate the US prevalence of uncorrectable visual impairment in 2050 accounting for changing distribution both age and myopia. Age projections population (from an estimated total 379 million 2050), were taken from census website. The myopia, by severity, was calculated literature-derived estimates 58.4% (≤ - 0.50 D, projection) 33.1% 1.00 1999-2004 estimate) to provide predicted conservative estimates, respectively. Uncorrectable as a function refractive error modelled multiple linear regression. Finally, likely number individuals with calculated. For projected myopia 58.4%, 222 are be myopic 48 will have high (- 5 D or worse). is 11.4 which 4.9 cases (43%) directly attributed increased risk eye disease associated 33.1%, 8.9 2.4 (27%) It that between 27 43% attributable Failure account increasing among aging leads substantial underestimate impairment.

Язык: Английский

---

Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety

BMC Ophthalmology, Год журнала: 2023, Номер 23(1)

Опубликована: Окт. 30, 2023

Abstract Background To investigate the efficacy and safety of 0.1% 0.01% low-dose atropine eye drops in reducing myopia progression Danish children. Methods Investigator-initiated, placebo-controlled, double-masked, randomized clinical trial. Ninety-seven six- to twelve-year old myopic participants were loading dose for six months followed by (loading group, Number (N) = 33), twelve (0.01% N 32) or vehicle (placebo, 32). Primary outcomes axial length spherical equivalent refraction. Secondary included adverse events reactions, choroidal thickness ocular biometry. Outcomes measured at baseline three-month intervals. Data was analyzed with linear-mixed model analysis according intention-to-treat. Results Mean elongation 0.10 mm less (95% confidence interval (CI): 0.17; 0.02, adjusted-p 0.06) 0.07 CI: 0.15; 0.00, 0.16) group compared placebo. refraction 0.24 D 0.05; 0.42) 0.19 0.00; 0.38) groups months, placebo (adjusted-p 0.06 0.14, respectively). A total 108 reported during initial six-month period, primarily 14 following switching, all deemed mild except two serious events, unrelated intervention. Conclusions Low-dose are safe over otherwise healthy There may be a modest but clinically relevant reduction children after treatment, effect statistically non-significant multiple comparisons adjustment. After dose-switching approached potentially indicating an early “rebound-effect”. Trial registration this study registered European Clinical Trials Database (EudraCT, number: 2018-001286-16) 05/11/2018 first posted www.clinicaltrials.gov (NCT03911271) 11/04/2019, prior initiation.

Язык: Английский

---